New study tracks immune clues in seniors with flu, RSV, and COVID-19

NCT ID NCT07643688

Not yet recruiting Knowledge-focused Sponsor: Fabiana Sherine Ganem dos Santos Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 150 adults aged 60 and older who have a respiratory infection (flu, RSV, or COVID-19) or who test negative. Researchers will measure specific immune markers in the blood over 60 days to see how they change from early infection to recovery. The goal is to better understand the body's immune response and find clues that could lead to new treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help identify new biomarkers for predicting disease severity and point toward future treatments that boost the immune system against respiratory viruses.
What could go wrong: This is an early observational study, not a treatment trial. It only looks at markers in the blood, so it cannot prove that any new therapy works. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY VIRAL INFECTION (INFLUENZA, RSV, OR SARS-COV-2) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 influenza respiratory syncytial virus infectious disease viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA INFECTION RSV INFECTIONS SARS-COV-2 INFECTION

More trials for these conditions

Other studies related to the condition(s) this trial covers.